Biohaven reports Q3 net loss $160.3M; troriluzole SCA trial positive, NDA submission planned Q4 2024

Biohaven Ltd.

2024-Q3 EPS reported -$7.50

Net loss $160.3M ($1.70/sh) vs $102.6M loss ($1.50/sh) in Q3 2023; non-GAAP adj. net loss $164.1M ($1.74/sh).
Cash position $642M as of Oct 2, 2024, including $269.9M net from Oct 2024 public offering of 6.05M shares at $47.50.
Troriluzole met primary endpoint in pivotal SCA trial; NDA submission to FDA on track for Q4 2024.
Initiated Phase 2 trial of BHV-2100 (TRPM3 antagonist) in acute migraine; expects Phase 3 SMA topline data in Q4 2024.
R&D expenses rose to $157.6M from $95.5M YoY due to advancing late-stage trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.